कैंसर अनुसंधान में पुरालेख

  • आईएसएसएन: 2254-6081
  • जर्नल एच-इंडेक्स: 13
  • जर्नल उद्धरण स्कोर: 3.58
  • जर्नल प्रभाव कारक: 3.12
में अनुक्रमित
  • चीन राष्ट्रीय ज्ञान अवसंरचना (सीएनकेआई)
  • उद्धरण कारक
  • ओसीएलसी- वर्ल्डकैट
  • पबलोन्स
  • चिकित्सा शिक्षा और अनुसंधान के लिए जिनेवा फाउंडेशन
  • गूगल ज्ञानी
  • गुप्त खोज इंजन लैब्स
इस पृष्ठ को साझा करें

अमूर्त

Lymphoma: Understanding the Complexities of Blood Cancer

Jennifer Fernandez

Lymphoma is a diverse group of blood cancers that originate from abnormal growth in the lymphatic system's lymphocytes, crucial cells of the immune system. It can be broadly classified into Hodgkin lymphoma and non-Hodgkin lymphoma (NHL), each encompassing various subtypes with unique characteristics and treatment approaches. The exact causes of lymphoma remains unclear, but certain risk factors, such as immune system disorders, viral infections, age, gender, and family history, are associated with increased susceptibility. Diagnosing lymphoma involves physical examination, blood tests, imaging studies, and lymph node biopsy. Treatment options depend on the type, stage, and individual factors, including chemotherapy, radiation therapy, immunotherapy, targeted therapy, and stem cell transplant. Advancements in research have led to improved treatments and outcomes for lymphoma patients, with ongoing clinical trials exploring innovative therapies. Early detection, accurate diagnosis, and timely intervention play a crucial role in enhancing patient outcomes. Public awareness, supports for research, and early screening efforts are essential in the fight against this complex group of blood cancers. Collaborative efforts from the medical community and the public can lead to better treatments and improved quality of life for individuals affected by lymphoma.

Keywords

Lymphoma; Blood cancers; Abnormal growth; Immunotherapy

अस्वीकृति: इस सारांश का अनुवाद कृत्रिम बुद्धिमत्ता उपकरणों का उपयोग करके किया गया है और इसे अभी तक समीक्षा या सत्यापित नहीं किया गया है।